Invida successfully markets the company’s branded pharmaceutical, biotechnology, medical device, and other healthcare products, including Consumer Health. Currently, Invida drives demand for more than 70 brands across 13 markets using the company’s proprietary methodology, EDGE™.  Building on our strengths in Dermatology, Primary Care, Consumer Health and Oncology, Invida has experienced a compound annual revenue growth of 23 percent.

EDGE™ Process
EDGE™ is Invida’s proprietary brand planning process, developed and implemented by Invida across all markets in Asia Pacific. The proven methodology is founded on our extensive commercialization expertise, market research, industry best practice, and a systematic approach to generating and applying knowledge of specific Asian customer insights. EDGE™. ensures consistency and optimal brand performance across highly fragmented and dynamic markets for Invida and our partners. It provides Invida with a significant market advantage, providing that successful “edge” for Invida marketed brands.

Invida’s brands encompass the Primary Care, Dermatology, Consumer Health and Oncology therapeutic classes.  Our leading brands include: Mestinon®, Distaclor/Ceclor®, Kefadim®, Vancocin®, Dermatix®, Kinerase®, Gly Derm®, OmegaGen®, Breacol®, and Actal®.